Concepedia

Publication | Open Access

Chemo-immunotherapy with dinutuximab beta in patients with relapsed/progressive high-risk neuroblastoma: does chemotherapy backbone matter?

DOIFull Paper Access

21

Citations

16

References

2024

Year

Patricia Raiser, Gudrun Schleiermacher, Marion Gambart, Benoît Dumont, Anne Sophie Defachelles, Estelle Thébaud, Julie Tandonnet, Claudia Pasqualini, Stéphanie Proust, Natacha Entz‐Werlé,
European Journal of Cancer

Abstract

Similar objective response rates for dB+TopoCyclo and dB+TOTEM/TEMIRI in patients with relapsed/progressive high-risk neuroblastoma emphasize the importance of chemo-immunotherapy, irrespective of the chemotherapy backbone.

References

YearCitations

Page 1